LY 3200882

Drug Profile

LY 3200882

Alternative Names: LY-3200882

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics
  • Mechanism of Action Immunomodulators; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 09 Nov 2016 Phase-I clinical trials in Solid tumours in USA, Australia, Canada, France, Spain (PO) (NCT02937272)
  • 17 Oct 2016 Preclinical trials in Solid tumours in USA (PO) prior to October 2016
  • 17 Oct 2016 Eli Lilly plans a phase I trial in Solid tumours in USA, Australia, Belgium, Canada, Switzerland, Germany, Denmark, Spain, France, Israel, Italy, South Korea, the Netherlands, Taiwan and United Kingdom (NCT02937272)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top